Antiviral activities of type I interferons to SARS-CoV-2 infection

Emily Mantlo, Natalya Bukreyeva, Junki Maruyama, Slobodan Paessler, Cheng Huang

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

Original languageEnglish (US)
Article number104811
JournalAntiviral research
StatePublished - Jul 2020


  • Antiviral therapy
  • COVID-19
  • Innate immune
  • Interferon
  • SARS-CoV-2

ASJC Scopus subject areas

  • Pharmacology
  • Virology


Dive into the research topics of 'Antiviral activities of type I interferons to SARS-CoV-2 infection'. Together they form a unique fingerprint.

Cite this